3rd Month Update
Due to the worsening condition of left lung pleural effusion, initially barely reaching 500cc during May, I underwent drainage every 2-3 weeks. Eventually, the volume increased to 1200-1400cc. Concerned about the severity, the doctor suggested self-funded treatment with Avastin (anti-angiogenic agent). In early July, I began this treatment. Additionally, because of bone metastasis, the doctor arranged for “Boneva,” which inhibits osteoclasts. However, it comes with side effects like hypertension and low blood calcium, prompting calcium supplement recommendations. Around a month after starting targeted therapy on July 10, the blood test showed no ROS1 gene mutation. The doctor explained that individuals initially detected with mutations but later undetected are less likely to develop drug resistance, allowing for prolonged targeted therapy. Approximately 40 days into the targeted therapy, by July 20, the MRI results revealed only 2 out of the initial 5 brain tumors remaining, all measuring less than 0.5 cm, indicating the effectiveness of the Entrectinib targeted therapy.